NUR 601 Module 6 System Analysis Example

A Loop Without a Brake: Primary Aldosteronism, Aldosterone Escape and Resistant Hypertension in a 42-Year-Old Woman

[Student Name]

Southern New Hampshire University

NUR 601: Advanced Pathophysiology

System Analysis

[Instructor Name]

[Date]

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

A Loop Without a Brake: Primary Aldosteronism, Aldosterone Escape and Resistant Hypertension in a 42-Year-Old Woman

Most hypertension has no single identifiable cause, but some does, and primary aldosteronism is the most common of the treatable ones. It is often missed because it looks like ordinary high blood pressure until the potassium falls or the pressure refuses to come down. This analysis examines a composite 42-year-old woman with resistant hypertension and low potassium. It argues that her adrenal gland is producing aldosterone outside normal feedback control, that the body's escape from sodium retention prevents edema but only by raising arterial pressure, and that locating the source of the excess determines whether she can be cured.

Normal Regulation

The renin-angiotensin-aldosterone system defends circulating volume and arterial pressure (Hall & Hall, 2021). Juxtaglomerular cells in the afferent arterioles of the kidney release renin when perfusion pressure falls, when the macula densa senses less sodium chloride and when sympathetic nerves stimulate them. Renin converts angiotensinogen to angiotensin I, which is converted to angiotensin II mainly in the lungs. Angiotensin II constricts arterioles and stimulates the zona glomerulosa of the adrenal cortex to release aldosterone. High serum potassium also stimulates aldosterone directly.

Aldosterone acts on principal cells in the collecting duct, increasing sodium channels and the sodium-potassium pump. Sodium is reabsorbed and water follows, while potassium is secreted into the urine; hydrogen ion secretion also increases. As volume and pressure recover, renin release falls, angiotensin II falls and aldosterone falls. This negative feedback is the brake that stops the system once its job is done.

The Case

She was diagnosed with hypertension at 36. Her pressure remains 162/98 mm Hg on full doses of amlodipine, lisinopril and hydrochlorothiazide, which meets the definition of resistant hypertension. She reports muscle cramps, fatigue and waking twice a night to urinate. She has no edema. Serum sodium is 143, potassium 3.2 and bicarbonate 30 mEq/L. After potassium was corrected, plasma aldosterone was 24 ng/dL and plasma renin activity 0.3 ng/mL/h, giving an aldosterone-to-renin ratio of 80.

Where Regulation Fails

Her aldosterone is high while her renin is almost undetectable. In a normal loop that combination should not occur, because high aldosterone would expand volume, suppress renin and then fall with it. Here the renin half of the loop is working: it has been suppressed by the volume and pressure aldosterone created. The failure is in the adrenal gland, which is releasing aldosterone without regard to renin. The most common sources are a single aldosterone-producing adenoma or hyperplasia of both adrenal glands (Funder et al., 2016).

The aldosterone-to-renin ratio is the recommended screening test for patients like her, including those with resistant hypertension or hypertension with low potassium (Funder et al., 2016). Two details strengthen her result. Potassium was corrected first, because low potassium suppresses aldosterone and could hide the excess. And she takes an ACE inhibitor, which normally raises renin; a suppressed renin despite that drug makes the finding more convincing.

Compensation: Aldosterone Escape

If aldosterone kept driving sodium retention without limit, she would become edematous. She is not, because of a compensation known as aldosterone escape. As sodium and water are retained over the first few days, arterial pressure and volume rise. Higher pressure in the kidney increases sodium excretion, a process called pressure natriuresis, and atrial stretch releases natriuretic peptides. Together these bring sodium output back into balance with intake at a new, higher level of volume and pressure (Hall & Hall, 2021).

The escape is incomplete in two important ways. First, it is achieved only at a higher arterial pressure, so the compensation itself sustains her hypertension. Second, it applies to sodium but not to potassium. Aldosterone continues to drive potassium and hydrogen secretion, which explains her low potassium and high bicarbonate. Her thiazide makes this worse by delivering more sodium to the collecting duct, where it is exchanged for potassium.

The Costs Beyond Blood Pressure

Aldosterone excess harms the heart and blood vessels beyond its effect on pressure, promoting inflammation and fibrosis. A meta-analysis found that patients with primary aldosteronism had higher risks of stroke, coronary artery disease, atrial fibrillation and heart failure than patients with essential hypertension (Monticone et al., 2018). Her muscle cramps and fatigue reflect low potassium, and her nocturia reflects the effect of low potassium on the kidney's ability to concentrate urine. These costs are why finding primary aldosteronism matters even when blood pressure could be controlled by adding more drugs.

Confirming and Locating the Source

A positive screening ratio is followed by a confirmatory test that shows aldosterone fails to suppress, such as a saline infusion. Her aldosterone remained above the suppression threshold after saline. Adrenal CT showed a 1.4 cm nodule on the left. Because small nodules can be nonfunctioning and bilateral disease can coexist, adrenal venous sampling is recommended for patients who want surgery; it compares aldosterone from each adrenal vein (Funder et al., 2016). Her sampling lateralized to the left.

The distinction determines treatment. A unilateral adenoma can be removed laparoscopically, often normalizing potassium and improving or curing the hypertension. Bilateral disease is treated with a mineralocorticoid receptor antagonist such as spironolactone, which blocks the action of aldosterone at its receptor.

Implications for Primary Care

The central lesson for a nurse practitioner is to suspect this diagnosis early. Primary aldosteronism is usually found only when someone looks for it, and many patients spend years adding drugs to a regimen that cannot fix the cause. A low potassium in a patient with hypertension, especially one that persists after the diuretic is stopped or corrected, should prompt screening rather than a potassium supplement alone. So should pressure that stays high on three drugs, or a new adrenal nodule found on a scan done for another reason.

Practical details affect the test. Potassium should be corrected first, and the result should be interpreted with the current medications in mind, because several common drugs change renin. When the ratio is positive, referral to an endocrinologist for confirmation and localization is appropriate. Until then, a mineralocorticoid receptor antagonist can be added if pressure or potassium demands it, although it will affect later testing and should be coordinated with the specialist.

Conclusion

This woman's hypertension has a specific cause: an adrenal nodule producing aldosterone outside the feedback that normally shuts it off. Her suppressed renin shows the rest of the loop is working, and her lack of edema shows aldosterone escape is holding sodium in balance, but only at a higher pressure and with continuing potassium loss. Tracing the loop from normal regulation to failure explains why screening was warranted, why the source needed to be located and why surgery offers her a possible cure.

References

Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F., Jr. (2016). The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 101(5), 1889-1916. https://doi.org/10.1210/jc.2015-4061

Hall, J. E., & Hall, M. E. (2021). Guyton and Hall textbook of medical physiology (14th ed.). Elsevier.

Monticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., & Mulatero, P. (2018). Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. The Lancet Diabetes & Endocrinology, 6(1), 41-50. https://doi.org/10.1016/S2213-8587(17)30319-4